INDUSTRIAL IMPACT

Inventors of biolayer interferometry technology launch a next gen platform and novel biosensors

Gator Bio | September 15, 2021

Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe. The GatorPlus adds to the currently available GatorPrime instrument; and the new Gator™ Flex SA Kit and Gator™ AAVX probe expand the off the shelf biosensor portfolio to 14 products for the North America market. Gator Bio also offers on demand custom biosensors for specific application needs. GatorPlus is a bench-top instrument for real-time label-free analysis of molecular interactions and quantitation in 96-well or 384-well microplates. The instrument offers longer walk-away time and more automation compared to GatorPrime, the first Gator instrument launched in March 2019.    

Based on Gator Bio's proprietary technology, the Gator™ Flex SA Kit is the industry's first ever reactivable streptavidin biosensor for BLI. It can be reactivated and reused more than 20 times without performance degradation, enabling significant cost saving for Gator system customers. The Gator™ AAVX probe quantitates many serotypes of AAVs automatically in minutes, greatly simplifying AAV developers' workflow. The results obtained from the Gator™ AAVX probes correlate tightly to the gold standard method.

Gator Bio was founded by Dr. Hong Tan and Mr. Robert Zuk, the pioneers of biolayer interferometry. The company has been focused on development and commercialization of the next generation BLI that greatly enhances the performance and cost effectiveness of this simple yet powerful analytical technology. In addition to the newly introduced Gator™ Flex SA Kit and Gator™ AAVX probes, Gator Bio offers a wide range of products, including the highly sensitive SMAP biosensor and the regenerable mouse Fc capture biosensor. The Gator systems and associated biosensors provide convenient kinetic analysis and concentration determination for the development of antibody and protein therapeutics.

 

"We saw problems and shortcomings with the original BLI technology, so we decided to come back to close the gaps with new ways to realize BLI. Our objective is to enable the most effective and efficient BLI systems for scientists".   

  - Dr. Hong Tan, CEO of Gator Bio. 


About Gator Bio,Inc.
Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. Gator Bio along with its sister company ET Healthcare are part of Access Medical Systems. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration and epitope binning, etc. Most importantly, Gator Bio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China.

Spotlight

How do you determine if your inventory is automation friendly? Do you want to automate your biobank? Chances are if you didn't take into account automation in your biobank, there are some serious challenges ahead for you. In this eBook, we focus on 10 considerations every biobank should think about.


Other News
DIAGNOSTICS

RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies

RQ Bio | May 17, 2022

RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of a successful licensing deal with AstraZeneca for RQ Bio's existing mAbs against SARS-CoV-2. The Company, which is headquartered in London, is dedicated to developing treatments and preventative therapies based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from existing, emerging and new viral infections. To maximise and accelerate patient impact, the company will continue to be supported by its collaborations with its scientific co-founders, the University of Oxford and leading UK medical research charity LifeArc. Professor Gavin Screaton, Head of the Medical Sciences Division at the University of Oxford, will continue to advise in his capacity as scientific and medical co-founder, as will Clare Terlouw, Head of LifeArc Ventures and UK BIA board member, as a member of the Board of Directors. Our vision is to build on our successful debut with neutralising antibody therapy for SARS-CoV-2 and develop innovative medicines to address current and evolving unmet needs in other viral infectious diseases, By combining our expertise and innovative excellence in core areas we have created a smarter approach to antibody generation making us uniquely positioned to deliver fast patient impact." Hugo Fry, CEO of RQ Bio. LifeArc is committed to backing leading UK academics and scientists, and we were inspired to fund RQ Bio because of the exceptional group of founders who are so passionately dedicated to finding new treatments and preventative therapies in areas of high unmet patient need, LifeArc provided support from across the Charity, including the venture team, scientific labs and other in-house experts to help RQ Bio execute on its business plan, and we look forward to further supporting RQ Bio as it becomes a world-leading infectious disease company." Clare Terlouw, Head of LifeArc Ventures. About RQ Bio RQ Bio's mission has been to develop medicines based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from current and future variants of viral infections. RQ Bio has achieved this by combining innovative excellence in core areas to create a smarter approach to antibody generation. RQ Bio has multiple sources of leads and a deep collaboration with the University of Oxford. RQ Bio was founded by scientific experts previously involved with the UK BIA Antibody Taskforce, which worked to build a community of infectious disease antibody experts focussed on the development of rapid and efficient delivery of highly potent neutralising antibodies to help support the UK COVID-19 response. About AstraZeneca Licensing Deal Under the terms of the agreement, RQ Bio has granted AstraZeneca an exclusive worldwide licence to develop, manufacture and commercialise RQ Bio's exisiting early stage mAbs against SARS-CoV-2 and a right of first refusal to take an exclusive licence in respect of any additional mAbs against SARS-CoV-2. RQ Bio will receive upfront and milestone payments of up to $157 million and will be eligible to receive single digit royalties on sales. The successful licensing deal was supported by Oxford University Innovation (OUI), a wholly-owned subsidiary of the University of Oxford that manages the University's technology transfer and consulting activities, who worked efficiently and creatively with all parties on the corresponding technology licences and the filing of intellectual properties.

Read More

MEDICAL

Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study

BioVaxys | June 09, 2022

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its Lyon, France-based bioproduction partner, BioElpida ("BioElpida"), has completed the creation of multiple OVCAR-3 cell banks as the next step in the GMP manufacturing process development for BVX-0918, BioVaxys' vaccine for treatment of platinum-resistant ovarian cancer. The OVCAR-3 cell line is mandatory for creating the identity assays that will have to be performed on every batch of ovarian cancer vaccine. This assay is required by regulatory bodies in the EU and United States. The cell line is derived from a human ovarian adenocarcinoma, established from a patient refractory to cisplatin, a chemotherapeutic agent used in late-stage ovarian cancer. Patients whose tumors are innately cisplatin-resistant at the time of initial treatment generally have poor prognosis, which is the patient population target for BVX-0918. Completion of OVCAR-3 cell banks is another step towards our ability to produce GMP yields of BVX-0918, and brings us closer to our Phase I study in the EU planned for later this year." BioVaxys President and Chief Operating Officer Kenneth Kovan. BioVaxys recently entered collaborations with Hospices Civils de Lyon in France and Deaconess Research Institute in the United States to provide the Company with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients. Tumor samples from both hospitals are being used to validate the tumor collection protocol, cryopackaging, cryopreservation, and supply chain logistics for BVX-0918 bioproduction for prospective patients in the US and EU. Tumor samples from HCL will also be used for process testing and manufacturing "dry runs" of BVX-0918, a major step leading to the completion of Good Manufacturing Process ("GMP") production. BioVaxys' vaccine platform is based on the established immunological concept that modifying surface proteins---whether they are viral or tumor---with haptens makes them more visible to the immune system. This process of haptenization "teaches" a patient's immune system to recognize and make target proteins more "visible" as foreign, thereby stimulating a T-cell mediated immune response. BioVaxys' cancer vaccines are created by extracting a patient's own (autologous) cancer cells, chemically linking with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic. Haptenization is a well-known and well-studied immunotherapeutic approach to cancer immunotherapy and has been clinically evaluated in both regional and disseminated metastatic tumors. A first generation single-hapten vaccine invented by BioVaxys Co-Founder and Chief Medical Officer David Berd, MD, achieved positive immunological and clinical results in Phase I and Phase II human trials in over 600 patients with different tumor types, as well as having no observed toxicity in years of clinical study. These studies were conducted under an FDA-reviewed IND. A first generation autologous, haptenized vaccine was also tested by Dr. Berd in women with advanced ovarian cancer who had ceased to respond to conventional chemotherapy. The results were encouraging: In 24 patients, the median overall survival was 25.4 months with a range of 4.5-57.4 months; 8 patients survived for more than 2 years. BioVaxys has enhanced the first-generation approach by utilizing two haptens ("bi-haptenization"), which the Company believes will yield superior results. About BioVaxys Technology Corp. Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).

Read More

INDUSTRIAL IMPACT

GluBio Completes Series A+ Financing of $22 Million to Advance the Development of Novel TPD Drugs

GluBio Therapeutics Inc | August 02, 2022

GluBio Therapeutics, a biotech company focused on developing novel targeted protein degradation (TPD) drugs, recently announced the completion of Series A+ financing of $22 million. This round is led by Qiming Venture Partners and joined by Lilly Asia Ventures and Kaitai Capital, bringing the total capital raised to nearly $90 million since its establishment in March, 2021. The investment will help advance two molecular glue degraders with best-in-class potential into the clinic for hematological malignancies, accelerate the lead optimization entry of three first-in-class TPD drugs for solid tumors and inflammatory diseases, and further upgrade GluBio's proprietary TPD discovery platform and screening capabilities tailored for rapid discovery and optimization of small molecule protein degraders for 'undruggable' therapeutic targets. "We are thrilled to advance molecular-glue and heterobifunctional protein degraders, which hold a great promise of eliminating disease-causing proteins that are not amenable to traditional therapeutic approaches. In the past 16 months, GluBio made tremendous progress in developing best-in-class and/or first-in-class TPD assets and state-of-the-art TPD platform, fully maximizing the therapeutic and commercial potential of TPD technologies. We completed this round within two months of Series A financing. We are grateful for the unwavering confidence investors have in our assets and platform, and confident that this round will accelerate a smooth and successful execution of our pipeline and platform." Gang Lu, Ph.D., GluBio Founder and CEO Dr. Kan Chen, Partner of Qiming Venture Parners, said, "Targeted protein degradation is a revolutionary technology in the biopharmaceutical field. GluBio team has extensive experience in targeted protein degradation and has built a strong platform for molecular glue and new target discovery technologies, making it a promising leader in TPD field. Qiming Venture Partners is pleased to continue our support to the company's development and hopes that GluBio will accelerate its R&D and industrialization process to bring more unmet need targets to the clinical stage and new treatment options to patients worldwide." About GluBio Therapeutics, Inc GluBio Therapeutics is a pioneering TPD company dedicated to developing targeted protein degraders for human diseases with unmet medical needs. Founded by seasoned drug developers with deep knowledge and expertise in TPD drug discovery, the company has established a proprietary TPD discovery platform and robust screening capability. GluBio is advancing a diverse pipeline of highly selective small-molecule degraders across multiple therapeutic areas including oncology and immunology. The company has research operations in both San Diego, CA, USA and Shanghai, China. About Qiming Venture Partners Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages. About Lilly Asia Ventures Founded in 2008, Lilly Asia Ventures is a leading biomedical venture capital firm with offices in Shanghai, Hong Kong, and Palo Alto. Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health. About Kaitai Capital Founded in 2009, Kaitai Capital is an investment management organization that mainly engages in venture capital, private equity, and wealth management businesses. Fields of investment include biotechnology, healthcare services, digital technology, agriculture technology and etc. Currently, the asset under management of Kaitai Capital has reached 50 billion RMB.

Read More

INDUSTRIAL IMPACT

Angel Yeast Partners with PhaBuilder to Open PHA Factory

Angel Yeast | July 27, 2022

Angel Yeast a globally listed yeast and yeast extract manufacturer, has inked an agreement with Bejing PhaBuilder Biotechnology Co., Ltd in Yichang, Hubei province to build a large manufacturing base for polyhydroxyalkanoates (PHA) in the city. The pair will set up a joint venture company to drive the application of synthetic biology in the biotechnology industry. PHA is a polyester produced naturally by microorganisms. The biodegradable and biocompatible properties of PHA make it highly sought-after in fields such as biomedical material and biodegradable packaging material. "This collaboration with PhaBuilder marks a milestone and a significant step forward for Angel Yeast in synthetic biology. At Angel Yeast, we are very keen on innovation and exploration of new landscapes in the industry. This project is also part of our efforts to be an international and professional biotechnology company," Tao Xiong, chairman of Angel Yeast He added that the partnership is expected to forge a new venture in bioeconomy, fuel innovation in synthetic biology, and drive the expansion of the global market. Guoqiang Chen, the founder of PhaBuilder, added that by working with Angel Yeast on the initiative, major inroads have been made in converting technology breakthroughs into industrial programs for synthetic biology. "The new production line of PHA with the capacity of 30,000 tons will certainly bring more advanced technologies, new services and products for the industry and consumers. It will also create a 'greener' lifestyle. We are thrilled to see it happen," said Chen. In addition to synthetic biology, Angel Yeast has also been exploring cutting-edge development in biological agriculture. According to the company, it will be engaged in a project to produce animal feed through biological fermentation. Angel Yeast will invest some 120 million yuan to build the manufacturing center with an annual capacity of 50,000 tons. The project is estimated to start in August 2022 and to be completed in September the next year. One highlight of the project is that it uses Distillers' Dried Grains with Solubles (DDGS) as one raw material to produce yeast culture products. As a new category, yeast culture products will diversify the company's animal nutrition products lineup. About Angel Yeast Founded in 1986, Angel Yeast Co., Ltd specializes in the production of yeast and yeast derivatives. Its product range includes baker's yeast and ingredients, Chinese dim sum and seasoning, savory yeast extract, human health, animal nutrition, plant nutrition, distilled spirits and biofuels, microbial nutrition, and enzymes.

Read More

Spotlight

How do you determine if your inventory is automation friendly? Do you want to automate your biobank? Chances are if you didn't take into account automation in your biobank, there are some serious challenges ahead for you. In this eBook, we focus on 10 considerations every biobank should think about.

Resources